Zhenbo Hu Selected Research

oridonin

1/2024	Differentiation of Acute Leukemia Cells Including Cells with MLL-AF4 Rearrangements Induced by Jiyuan Oridonin A.
1/2023	Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A.
1/2022	Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells.
1/2021	Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhenbo Hu Research Topics

Disease

11	Leukemia 01/2024 - 06/2011
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2023 - 01/2016
10	Neoplasms (Cancer) 01/2023 - 01/2011
3	Carcinogenesis 12/2022 - 04/2016
3	Acute Promyelocytic Leukemia 01/2022 - 01/2021
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2023 - 09/2020
1	Thrombocytopenia (Thrombopenia) 11/2022
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 08/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Microsatellite Instability 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Colonic Neoplasms (Colon Cancer) 01/2017
1	Myeloid Leukemia (Leukemia, Myelocytic) 05/2014
1	Melanoma (Melanoma, Malignant) 07/2012
1	Renal Cell Carcinoma (Grawitz Tumor) 02/2011

Drug/Important Bio-Agent (IBA)

4	oridoninIBA 01/2024 - 01/2021
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022 - 01/2018
3	Histone DemethylasesIBA 07/2023 - 01/2020
3	Proteins (Proteins, Gene)FDA Link 07/2023 - 01/2011
3	Transcription Factors (Transcription Factor)IBA 01/2023 - 01/2016
3	Histone Deacetylase InhibitorsIBA 01/2022 - 01/2022
3	Histones (Histone)IBA 01/2021 - 06/2011
2	LipidsIBA 09/2022 - 08/2022
2	TransferasesIBA 01/2017 - 07/2012
2	Decitabine FDA Link 01/2017 - 07/2012
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 07/2012
2	DeoxycytidineIBA 01/2017 - 07/2012
2	Co-Repressor ProteinsIBA 05/2014 - 06/2011
1	gamma-Aminobutyric Acid (GABA)IBA 07/2023
1	Imatinib Mesylate (Gleevec)FDA Link 01/2023
1	Oncogene Proteins (Oncogene Protein)IBA 12/2022
1	Thrombopoietin (c-mpl Ligand)IBA 11/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2022
1	lysophosphatidic acidIBA 08/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	GlycolipidsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	honokiolIBA 01/2022
1	Arsenic Trioxide (Trisenox)FDA Link 01/2021
1	Tadalafil (Cialis)FDA Link 01/2021
1	DiterpenesIBA 01/2021
1	Kaurane DiterpenesIBA 01/2021
1	Lysine (L-Lysine)FDA Link 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2020
1	Enhancer of Zeste Homolog 2 ProteinIBA 04/2020
1	KLA peptideIBA 04/2020
1	Peptides (Polypeptides)IBA 04/2020
1	Cell-Penetrating PeptidesIBA 04/2020
1	molibresibIBA 01/2020
1	AZD5153IBA 01/2020
1	CPI-0610IBA 01/2020
1	INCB054329IBA 01/2020
1	PLX51107IBA 01/2020
1	mivebresibIBA 01/2020
1	INCB057643IBA 01/2020
1	ODM-207IBA 01/2020
1	NucleophosminIBA 10/2018
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2017
1	mirfentanilIBA 01/2017
1	NucleosidesIBA 01/2017
1	MicroRNAs (MicroRNA)IBA 04/2016
1	Carrier Proteins (Binding Protein)IBA 01/2016
1	TetrahydrouridineIBA 07/2012
1	entinostat (MS 275)IBA 06/2011
1	Vorinostat FDA Link 06/2011
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2011
1	Tumor Biomarkers (Tumor Markers)IBA 01/2011
1	HLA-G Antigens (HLA G)IBA 01/2011

Therapy/Procedure

3	Therapeutics 01/2022 - 05/2014
2	Drug Therapy (Chemotherapy) 07/2012 - 02/2011
1	Immunotherapy 01/2022